Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (1435)	11/17/1998 9:06:00 AM
From: Biomaven	Read Replies (1) of 10280

V1, My take on this early data is that it is comparable to Detrol and better than straight oxy, but not as good as the numbers claimed by Alza for their time-release version. I view it as a viable drug, with the distinct possibility that a time-release version would be better than the Alza drug. From what I heard, SEPR has been beating the drums for ages saying that they didn't know if it was going to show efficacy at all. I certainly didn't hear that "the company had been encouraging enthusiasm in advance of the release." (S)-oxy is quite different from all their other single isomer drugs, in that the two isomers have different modes of action, not just different side effects. Thus Maris's attempt to say that the data "shows the risks of single isomer development" means that he either doesn't understand this, or he does understand it and he's just mad at the company. In general he seems more concerned with Alza than SEPR. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next